Biogen (BIIB +0.88%) hasn’t been an excellent inventory to possess for the reason that flip of the last decade. The corporate confronted a number of demanding situations, together with biosimilar festival in its more than one sclerosis (MS) franchise and business setbacks within the Alzheimer’s illness (AD) marketplace. On the other hand, zooming out offers us an overly other image. Over the last 3 a long time, Biogen’s stocks have outperformed broader equities.
BIIB Overall Go back Stage knowledge through YCharts
May the corporate leap again from contemporary headwinds and nonetheless ship market-beating returns to affected person buyers?
What the long run holds
Biogen’s monetary effects have not been nice in recent times. In 2025, the corporate’s income of $9.9 billion larger through simplest 2% yr over yr, whilst its adjusted income according to proportion dropped through 7% to $15.28. Weak spot inside of Biogen’s MS franchise, in addition to stiff festival it has encountered for Spinraza, a drugs for spinal muscular atrophy (a genetic illness that reasons muscle weak spot), are dragging gross sales enlargement down.
On the other hand, more recent launches and label expansions may just assist spice up income enlargement. Believe Biogen’s Leqembi, a drugs for Alzheimer’s illness (AD) that first earned approval in 2023. Since then, it has won further indications, significantly as a subcutaneous injection in upkeep dosing. This implies sufferers can obtain it from the relief in their houses — as an alternative of getting to visit healthcare amenities for intravenous infusion — which will have to assist spice up the medication’s adoption.
Symbol supply: Getty Pictures.
Additional, Leqembi may just quickly obtain the fairway mild for subcutaneous management for remedy initiation (at the moment, sufferers nonetheless want to see clinical execs to start out remedy sooner than choosing at-home subcutaneous injections). Leqembi’s gross sales are rising speedy. Final yr, Biogen’s proportion of income from it — it co-markets Leqembi with Eisai — was once $178 million, up 197% yr over yr.
Those label expansions may just ship its gross sales even upper. Biogen additionally won acclaim for a high-dose system of Spinraza that posted upper efficacy in medical trials and calls for fewer preliminary doses, a bonus that might assist it compete with different medications on this area of interest.
These days’s Exchange
(0.88%) $1.58
Present Value
$180.54
Key Information Issues
Marketplace Cap
$26B
Day’s Vary
$177.70 – $180.87
52wk Vary
$114.66 – $202.41
Quantity
1K
Avg Vol
1.3M
Gross Margin
66.60%
Then, there are different more recent merchandise like Skyclarys, authorized for Friedreich’s Ataxia, an extraordinary neuromuscular illness, and Zurzuvae, a drugs for postpartum melancholy. Those may just additionally assist the biotech corporate go back to forged top-line enlargement. Past those merchandise, Biogen has expanded its pipeline via acquisitions over the last few years. It nonetheless has sexy applicants in a few of its core spaces.
However the corporate’s possibilities are rather unsure, as income enlargement would possibly not rebound this yr, regardless of the brand new approvals and label expansions. According to Biogen’s personal steering, its gross sales will lower on a year-over-year foundation in 2026. There’s nonetheless an opportunity it’ll recuperate in a couple of years, however older merchandise are obviously nonetheless suffering sufficient to offset the growth of more recent ones. That implies Biogen has so much using on its pipeline applicants and on new drug launches to make vital headway, with little room for error.
In different phrases, this healthcare inventory appears dangerous at the moment and is, at this level, not going to make buyers wealthy over the longer term. Biogen’s stocks may just jump within the subsequent 5 years with near-flawless execution of its technique, however simplest buyers happy with heightened chance will have to imagine the inventory.
